GT Biopharma Inc. Common Stock (GTBP) is a publicly traded Healthcare sector company. As of July 28, 2026, GTBP trades at $0.32 with a market cap of $11.70M and a P/E ratio of -0.05. GTBP moved -2.63% today. Year to date, GTBP is -57.45%; over the trailing twelve months it is -83.78%. Its 52-week range spans $0.26 to $4.10. Rallies surfaces GTBP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
GT Biopharma Integrates AI to Advance Multiple Tumor-Targeting Candidates into Pre-IND by 2027: GT Biopharma has embedded AI-based tools into the discovery and protein-engineering of its tumor-targeting NK cell engagers and multi-domain proteins to accelerate design and reduce development costs. Efficiency gains are expected to advance multiple new candidates into pre-IND development in 2027.
| Metric | Value |
|---|---|
| Price | $0.32 |
| Market Cap | $11.70M |
| P/E Ratio | -0.05 |
| EPS | $-6.68 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.10 |
| 52-Week Low | $0.26 |
| Volume | 55.39K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-28.35M |
| Gross Margin | 0.00% |
GTBP analyst coverage data. Average price target: $0.00.